Basilea Pharmaceutica AG, Allschwil Stock: price and insider trades · Switzerland

Basilea Pharmaceutica AG, headquartered in Allschwil, is a Swiss biopharmaceutical company listed on SIX Swiss Exchange (SMI/SPI) in Switzerland under the ticker BSLN. Founded in 2000 and listed in 2004, Basilea has evolved from a broader R&D organization into a commercial-stage specialty company focused on severe bacterial and fungal infections. Its strategic positioning is centered on areas of high unmet medical need, where antimicrobial resistance, life-threatening disease burden, and limited treatment alternatives support a differentiated and relatively defensive investment case. The company combines marketed products, licensing/partner-led commercialization, and a development pipeline, giving it a mix of recurring revenue exposure and pipeline optionality.

Basilea’s business model is built around two main pillars. First, it commercializes anti-infective medicines through international partners, limiting the need for a large proprietary sales force while preserving economic upside. Second, it advances new assets in its core therapeutic franchise. Key products and assets include Zevtera® (ceftobiprole medocaril), which became commercially available in the United States through partner Innoviva Specialty Therapeutics in 2025, and Cresemba®/isavuconazole, a major anti-infective asset historically important to the group through licensing and distribution arrangements. On the pipeline side, Basilea is advancing fosmanogepix, a first-in-class antifungal, and BAL2062. In 2025, the company initiated a phase 3 study for fosmanogepix in invasive mold infections and also received an additional USD 39 million from BARDA to continue development of fosmanogepix and BAL2062, underscoring external validation of the franchise.